Nuvalent Inc (NASDAQ:NUVL) – Research analysts at Piper Sandler decreased their Q3 2021 earnings estimates for shares of Nuvalent in a research note issued on Wednesday, September 8th. Piper Sandler analyst C. Raymond now forecasts that the company will post earnings per share of ($0.22) for the quarter, down from their prior forecast of ($0.20). Piper Sandler has a “Overweight” rating and a $40.00 price target on the stock. Piper Sandler also issued estimates for Nuvalent’s Q4 2021 earnings at ($0.29) EPS, FY2021 earnings at ($1.60) EPS and Q1 2022 earnings at ($0.35) EPS.
Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings results on Wednesday, September 8th. The company reported ($3.17) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($2.97).
Shares of NUVL stock opened at $37.50 on Monday. Nuvalent has a twelve month low of $17.00 and a twelve month high of $40.82.
Nuvalent Inc is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company’s program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc is based in CAMBRIDGE, Mass.
See Also: Dividend Yield
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.